(Las Vegas, Nevada, United States) As per DelveInsight’s assessment, globally, Pyelonephritis pipeline constitutes 20+ key companies continuously working towards developing 20+ Pyelonephritis treatment therapies, analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments analyzes DelveInsight.
“Pyelonephritis Pipeline Insight, 2024″ report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the Pyelonephritis Market.
The Pyelonephritis Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the drug, including the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers acquisition, funding, designations, and other product-related details.
Request for Sample Report here @ Pyelonephritis Pipeline Analysis
Some of the key takeaways from the Pyelonephritis Pipeline Report:
- Pyelonephritis Companies across the globe are diligently working toward developing novel Pyelonephritis treatment therapies with a considerable amount of success over the years.
- Pyelonephritis companies working in the treatment market are Wockhardt, Sinovent, Entasis Therapeutics, Melinta Therapeutics, Allecra Therapeutics GmbH, Entasis Therapeutics Holdings Inc, Iterum Therapeutics Plc, Jiangsu Sinoyoung Bio-Pharmaceutical Co Ltd, Meiji Seika Pharma Co Ltd, Merck & Co Inc, MerLion Pharmaceuticals Pte Ltd, Nabriva Therapeutics Plc, Paratek Pharmaceuticals Inc, Pfizer Inc, Qilu Pharmaceutical Co Ltd, VenatoRx Pharmaceuticals Inc, XuanZhu Biological Technology Co Ltd and others, are developing therapies for the Pyelonephritis treatment.
- Emerging Pyelonephritis therapies such as WCK-5222, XNW 4107, ETX2514SUL and others are expected to have a significant impact on the Pyelonephritis market in the coming years.
- On December 2023, Wockhardt announced results of a Phase 3, Randomized, Double-blind, Multicenter, Comparative Study to Determine the Efficacy and Safety of Cefepime-zidebactam vs. Meropenem in the Treatment of Complicated Urinary Tract Infection or Acute Pyelonephritis in Adults.
- On June 2023, Meiji Seika Pharma Co., Ltd announced results of a Phase 3, Multi-Center, Randomized, Double-Blind Study to Evaluate the Efficacy and Safety of Cefepime/Nacubactam or Aztreonam/Nacubactam Compared to Imipenem/Cilastatin in the Treatment of Complicated Urinary Tract Infections or Acute Uncomplicated Pyelonephritis, in Adults.
Pyelonephritis Overview
Pyelonephritis is a bacterial infection of the kidneys, typically stemming from a urinary tract infection (UTI) that ascends to the kidneys. It commonly affects women and can occur suddenly (acute pyelonephritis) or develop gradually (chronic pyelonephritis). The most common causative agent is Escherichia coli, though other bacteria can also be responsible.
Symptoms of pyelonephritis may include fever, chills, flank pain (pain in the side or back), nausea, vomiting, and frequent urination. In severe cases, individuals may experience confusion or symptoms of sepsis, a life-threatening condition characterized by systemic inflammation in response to infection.
Pyelonephritis Diagnosis typically involves a physical examination, urinalysis, urine culture, and imaging studies such as ultrasound, CT scan, or MRI to assess kidney involvement and rule out complications like abscess formation or kidney stones.
Pyelonephritis Treatment often involves antibiotics to eradicate the bacterial infection. In severe cases or those involving complications, hospitalization may be necessary for intravenous antibiotic therapy and supportive care. Adequate hydration is important to help flush out bacteria from the urinary tract. Patients may also require pain management and medications to alleviate fever and discomfort.
Untreated or recurrent pyelonephritis can lead to complications such as kidney damage, abscess formation, sepsis, or even kidney failure, emphasizing the importance of prompt diagnosis and treatment. Additionally, preventive measures such as good hygiene, proper hydration, and prompt treatment of UTIs can help reduce the risk of developing pyelonephritis.
Get a Free Sample PDF Report to know more about Pyelonephritis Pipeline Therapeutic Assessment- Pyelonephritis Treatment Market
Pyelonephritis Route of Administration
Pyelonephritis pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs, such as
- Intra-articular
- Intraocular
- Intrathecal
- Intravenous
- Ophthalmic
- Oral
- Parenteral
- Subcutaneous
- Topical
- Transdermal
Pyelonephritis Molecule Type
Pyelonephritis Products have been categorized under various Molecule types, such as
- Oligonucleotide
- Peptide
- Small molecule
Pyelonephritis Pipeline Therapeutics Assessment
- Pyelonephritis Assessment by Product Type
- Pyelonephritis By Stage and Product Type
- Pyelonephritis Assessment by Route of Administration
- Pyelonephritis By Stage and Route of Administration
- Pyelonephritis Assessment by Molecule Type
- Pyelonephritis by Stage and Molecule Type
DelveInsight’s Pyelonephritis Pipeline Report covers around 20+ products under different phases of clinical development like-
- Late-stage products (Phase III)
- Mid-stage products (Phase II)
- Early-stage product (Phase I)
- Pre-clinical and Discovery stage candidates
- Discontinued & Inactive candidates
- Route of Administration
Further Pyelonephritis product details are provided in the report. Download the Pyelonephritis pipeline report to learn more about the emerging Pyelonephritis therapies- Pyelonephritis Clinical Trials and FDA Approvals
Pyelonephritis Pipeline Analysis:
The Pyelonephritis pipeline report provides insights into
- The report provides detailed insights about companies that are developing therapies for the treatment of Pyelonephritis with aggregate therapies developed by each company for the same.
- It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Pyelonephritis Treatment.
- Pyelonephritis key companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
- Pyelonephritis Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
- Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Pyelonephritis market.
Download Sample PDF Report to know more about Pyelonephritis drugs and therapies- Pyelonephritis Clinical Trials and FDA Approvals
Scope of Pyelonephritis Pipeline Drug Insight
- Coverage: Global
- Key Pyelonephritis Companies: Wockhardt, Sinovent, Entasis Therapeutics, Melinta Therapeutics, Allecra Therapeutics GmbH, Entasis Therapeutics Holdings Inc, Iterum Therapeutics Plc, Jiangsu Sinoyoung Bio-Pharmaceutical Co Ltd, Meiji Seika Pharma Co Ltd, Merck & Co Inc, MerLion Pharmaceuticals Pte Ltd, Nabriva Therapeutics Plc, Paratek Pharmaceuticals Inc, Pfizer Inc, Qilu Pharmaceutical Co Ltd, VenatoRx Pharmaceuticals Inc, XuanZhu Biological Technology Co Ltd and others.
- Key Pyelonephritis Therapies: WCK-5222, XNW 4107, ETX2514SUL and others.
- Pyelonephritis Therapeutic Assessment: Pyelonephritis current marketed and Pyelonephritis emerging therapies
- Pyelonephritis Market Dynamics: Pyelonephritis market drivers and Pyelonephritis market barriers
Request for Sample PDF Report for Pyelonephritis Pipeline Assessment and clinical trials – Pyelonephritis Therapeutics Market
Table of Contents
1. Pyelonephritis Report Introduction
2. Pyelonephritis Executive Summary
3. Pyelonephritis Overview
4. Pyelonephritis- Analytical Perspective In-depth Commercial Assessment
5. Pyelonephritis Pipeline Therapeutics
6. Pyelonephritis Late Stage Products (Phase II/III)
7. Pyelonephritis Mid Stage Products (Phase II)
8. Pyelonephritis Early Stage Products (Phase I)
9. Pyelonephritis Preclinical Stage Products
10. Pyelonephritis Therapeutics Assessment
11. Pyelonephritis Inactive Products
12. Company-University Collaborations (Licensing/Partnering) Analysis
13. Pyelonephritis Companies
14. Pyelonephritis Key Products
15. Pyelonephritis Unmet Needs
16 . Pyelonephritis Market Drivers and Barriers
17. Pyelonephritis Future Perspectives and Conclusion
18. Pyelonephritis Analyst Views
19. Appendix
20. About DelveInsight
About DelveInsight
DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate business growth and overcome challenges with a practical approach.
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Ankit Nigam
Email: Send Email
Phone: +14699457679
Address:304 S. Jones Blvd #2432, Las Vegas NV 89107
City: Albany
State: New York
Country: United States
Website: https://www.delveinsight.com/consulting/conference-coverage-services
Press Release Distributed by ABNewswire.com
To view the original version on ABNewswire visit: Pyelonephritis Clinical Trials Analysis 2024: FDA Approvals, Therapies, Mechanism of Action, Route of Administration, and Companies by DelveInsight